Advertisement
Screener

Edwards Lifesciences Corporation (EW) Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

Edwards Lifesciences Corporation Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest

Edwards Lifesciences Corporation (EW) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity · last filed 2026-05-06

  • Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2026-03-31 was $0.00.
  • Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2025-12-31 was $0.00.
  • Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$800.00K.
  • Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$1.70M.
  • Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2025 was -$4.10M.
  • Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2024 was -$4.90M.
  • Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2023 was -$3.00M.
  • Edwards Lifesciences Corporation income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2022 was $0.00.
Period endIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 12 month
2026-03-31$0.00
10-Q · filed 2026-05-06
$0.00
derived: sum of 2 quarters · filed 2026-05-06
-$800.00K
derived: sum of 3 quarters · filed 2026-05-06
-$2.50M
derived: sum of 4 quarters · filed 2026-05-06
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$800.00K
derived: sum of 2 quarters · filed 2026-02-25
-$2.50M
derived: sum of 3 quarters · filed 2026-02-25
-$4.10M
10-K · filed 2026-02-25
2025-09-30-$800.00K
10-Q · filed 2025-11-05
-$2.50M
derived: sum of 2 quarters · filed 2025-11-05
-$4.10M
10-Q · filed 2025-11-05
-$5.40M
derived: sum of 4 quarters · filed 2026-05-06
2025-06-30-$1.70M
10-Q · filed 2025-08-06
-$3.30M
10-Q · filed 2025-08-06
-$4.60M
derived: sum of 3 quarters · filed 2026-05-06
-$6.00M
derived: sum of 4 quarters · filed 2026-05-06
2025-03-31-$1.60M
10-Q · filed 2026-05-06
-$2.90M
derived: sum of 2 quarters · filed 2026-05-06
-$4.30M
derived: sum of 3 quarters · filed 2026-05-06
-$5.60M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31-$1.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$2.70M
derived: sum of 2 quarters · filed 2026-02-25
-$4.00M
derived: sum of 3 quarters · filed 2026-02-25
-$4.90M
10-K · filed 2026-02-25
2024-09-30-$1.40M
10-Q · filed 2025-11-05
-$2.70M
derived: sum of 2 quarters · filed 2025-11-05
-$3.60M
10-Q · filed 2025-11-05
-$3.80M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30-$1.30M
10-Q · filed 2025-08-06
-$2.20M
10-Q · filed 2025-08-06
-$2.40M
derived: sum of 3 quarters · filed 2026-02-25
-$3.60M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31-$900.00K
10-Q · filed 2025-05-06
-$1.10M
derived: sum of 2 quarters · filed 2026-02-25
-$2.30M
derived: sum of 3 quarters · filed 2026-02-25
-$3.90M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31-$200.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
-$1.40M
derived: sum of 2 quarters · filed 2026-02-25
-$3.00M
derived: sum of 3 quarters · filed 2026-02-25
-$3.00M
10-K · filed 2026-02-25
2023-09-30-$1.20M
10-Q · filed 2024-11-06
-$2.80M
derived: sum of 2 quarters · filed 2024-11-06
-$2.80M
10-Q · filed 2024-11-06
2023-06-30-$1.60M
10-Q · filed 2024-07-31
-$1.60M
10-Q · filed 2024-07-31
2022-12-31$0.00
10-K · filed 2025-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
STERIS plc (STE)Ireland$20.343B25.49
ZIMMER BIOMET HOLDINGS, INC. (ZBH)United States$17.103B20.66
ALIGN TECHNOLOGY INC (ALGN)United States$10.346B29.06
MSA Safety Inc (MSA)United States$7.023B21.47
ESTABLISHMENT LABS HOLDINGS INC. (ESTA)$1.954B-65.76
Cadre Holdings, Inc. (CDRE)United States$1.123B33.88
Enovis CORP (ENOV)United States$1.053B-1.18
Anteris Technologies Global Corp. (AVR)United States$0.746B
Sanara MedTech Inc. (SMTI)United States$0.323B-6.81
Inogen Inc (INGN)United States$0.139B-7.00